When ACBI2 was dosed orally in a SMARCA2-sensitive mouse xenograft model, almost complete degradation of SMARCA2 was achieved although this was associated with tumour stasis rather than the hoped-for regression. This evidence concerns the gene SMARCA2 and neoplasm.